Anti-CTLA4, anti-PD1, and anti-PDL1 therapy have achieved robust success across multiple cancer types, including melanoma, non-small-cell lung cancer (NSCLC), and colorectal cancer [16]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.